Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Rating of “Moderate Buy” by Analysts

Gossamer Bio, Inc. (NASDAQ:GOSS) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $8.50.

Several analysts recently issued reports on GOSS shares. Wall Street Zen raised shares of Gossamer Bio from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a research report on Wednesday, October 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Gossamer Bio in a report on Thursday, September 11th.

Gossamer Bio Stock Performance

NASDAQ GOSS opened at $3.43 on Friday. The business has a fifty day moving average price of $2.84 and a 200 day moving average price of $2.30. The company has a market cap of $793.91 million, a P/E ratio of -4.97 and a beta of 1.92. Gossamer Bio has a one year low of $0.76 and a one year high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $13.29 million for the quarter, compared to analysts’ expectations of $6.32 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%. As a group, sell-side analysts predict that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC lifted its holdings in Gossamer Bio by 24.6% in the first quarter. Acadian Asset Management LLC now owns 6,358,113 shares of the company’s stock valued at $6,991,000 after acquiring an additional 1,253,353 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Gossamer Bio by 720.2% in the first quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock valued at $1,034,000 after purchasing an additional 825,047 shares during the period. OMERS ADMINISTRATION Corp acquired a new position in shares of Gossamer Bio in the 1st quarter valued at $387,000. ProShare Advisors LLC purchased a new position in shares of Gossamer Bio during the 2nd quarter worth $48,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Gossamer Bio during the 2nd quarter worth about $53,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.